Leqvio (Inclisiran) and Diphenhydramine Interaction

Why This Combination Raises Questions

Patients prescribed Leqvio (inclisiran) for atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) often reach for diphenhydramine, a widely available first-generation antihistamine sold as Benadryl and dozens of store-brand equivalents. The concern is reasonable: diphenhydramine interacts with a long list of medications through CYP2D6 inhibition and anticholinergic burden [1]. Inclisiran, however, belongs to a drug class (siRNA therapeutics) that bypasses the CYP enzyme system entirely.

How the Concern Typically Arises

Most drug-interaction databases flag diphenhydramine as a moderate CYP2D6 inhibitor. Patients who see warnings about combining it with statins or other cardiovascular drugs often assume the same caution applies to inclisiran. That assumption does not hold, because inclisiran is not a small-molecule drug processed by the liver's cytochrome P450 machinery.

What the FDA Labels Say

The inclisiran prescribing information (revised 2021) states that no clinically significant drug-drug interactions have been identified with inclisiran in clinical studies [2]. The diphenhydramine label, by contrast, lists interactions primarily with CNS depressants, MAO inhibitors, and other anticholinergic agents [3]. Neither label references the other drug.

Inclisiran Pharmacology: A Non-CYP Drug

Inclisiran is a synthetic double-stranded siRNA conjugated to triantennary N-acetylgalactosamine (GalNAc). After subcutaneous injection, the GalNAc moiety delivers inclisiran specifically to hepatocyte asialoglycoprotein receptors (ASGPR). Inside the hepatocyte, inclisiran binds to the RNA-induced silencing complex (RISC) and catalytically degrades PCSK9 messenger RNA, reducing PCSK9 protein synthesis and increasing LDL receptor recycling [4].

Metabolism and Clearance

This is where the interaction question resolves. Inclisiran is degraded by endogenous nucleases into inactive nucleotide fragments. It does not undergo Phase I oxidation (CYP450) or Phase II conjugation (glucuronidation, sulfation). Renal excretion accounts for roughly 16% of intact drug elimination [2]. Because inclisiran never passes through the enzymatic pathways that diphenhydramine inhibits or competes with, no pharmacokinetic collision occurs.

Protein Binding

Inclisiran shows moderate plasma protein binding (87%), primarily to albumin. Diphenhydramine is approximately 78% protein-bound [3]. While both drugs bind albumin, the concentrations at therapeutic doses are far too low for meaningful displacement. Inclisiran's peak plasma concentration after a 284 mg dose is transient (Tmax ~4 hours) and rapidly clears to sub-detectable levels between doses [2].

Diphenhydramine Pharmacology and Its Interaction Profile

Diphenhydramine is a first-generation H1-receptor antagonist with well-characterized anticholinergic, sedative, and CYP-inhibitory properties. Its primary metabolic pathway runs through CYP2D6, with secondary contributions from CYP1A2, CYP2C9, and CYP2C19 [5]. The drug reaches peak plasma concentration within 1 to 3 hours of oral administration, has a half-life of 4 to 8 hours in adults, and is excreted renally as inactive metabolites.

CYP2D6 Inhibition

Diphenhydramine is a moderate CYP2D6 inhibitor. This matters when it is co-administered with drugs that depend on CYP2D6 for activation or clearance: codeine, tamoxifen, metoprolol, and several antidepressants. It does not matter for inclisiran, which never encounters CYP2D6.

Anticholinergic Burden

The anticholinergic effects of diphenhydramine (dry mouth, urinary retention, constipation, tachycardia, cognitive impairment) are independent of inclisiran. A 2019 JAMA Internal Medicine study (N=284,343) linked cumulative anticholinergic exposure to increased dementia risk [6]. Clinicians should evaluate anticholinergic burden in any patient over 65, but this concern applies to diphenhydramine's standalone profile and is not amplified by inclisiran.

Pharmacodynamic Considerations

A pharmacodynamic interaction requires two drugs to affect the same physiological pathway. Inclisiran's pharmacodynamic target is PCSK9 synthesis in hepatocytes, resulting in LDL-C reduction. Diphenhydramine's pharmacodynamic targets are H1 histamine receptors, muscarinic acetylcholine receptors, and sodium channels. These targets do not overlap.

Cardiac Electrophysiology

Diphenhydramine at supratherapeutic doses can prolong the QTc interval through sodium and potassium channel blockade [7]. Inclisiran has not demonstrated QTc effects in dedicated thorough QT studies [2]. Co-administration does not create additive QTc risk. Patients taking diphenhydramine alongside other QTc-prolonging drugs should still receive appropriate monitoring, but inclisiran does not contribute to that concern.

Injection-Site Reactions and Antihistamine Use

A practical consideration: injection-site reactions (ISRs) are the most common adverse effect of inclisiran, occurring in 8.2% of patients in the ORION-10 trial (N=1,561) versus 1.8% on placebo [8]. These reactions are typically mild (erythema, pain, rash) and resolve within days. Some clinicians have suggested pre-treatment with an antihistamine. Diphenhydramine could theoretically serve this purpose, though no clinical trial data support routine antihistamine pre-medication for inclisiran ISRs.

Clinical Trial Evidence: ORION Program

The ORION clinical trial program provides the primary safety database for inclisiran. ORION-9 (HeFH, N=482), ORION-10 (ASCVD, N=1,561), and ORION-11 (ASCVD/risk equivalents, N=1,617) enrolled patients on diverse concomitant medications [8][9][10].

Concomitant Medication Data

In pooled analyses from ORION-10 and ORION-11 (combined N=3,178), inclisiran produced a 52% placebo-adjusted reduction in LDL-C at day 510 [8]. Participants in these trials were permitted to use over-the-counter medications including antihistamines. No signal of interaction with antihistamines emerged in safety analyses, though individual OTC agents were not broken out by name in published results.

ORION-4 Cardiovascular Outcomes

The ORION-4 trial (N=15,968), designed to assess cardiovascular outcomes with inclisiran versus placebo over a median follow-up of approximately 5 years, reported its primary results showing significant LDL-C reduction sustained over the trial period [11]. The trial's large population and long duration would have been expected to surface any clinically meaningful drug interactions with commonly used OTC products.

Populations Requiring Special Attention

Older Adults (Age 65+)

Patients over 65 prescribed inclisiran are more likely to experience diphenhydramine-related adverse effects: excessive sedation, falls, urinary retention, and cognitive impairment. The American Geriatrics Society Beers Criteria lists diphenhydramine as a potentially inappropriate medication in older adults due to its strong anticholinergic properties [12]. This recommendation stands irrespective of inclisiran. A second-generation antihistamine (cetirizine, loratadine, fexofenadine) carries less anticholinergic risk.

Hepatic Impairment

Inclisiran exposure increases modestly in mild hepatic impairment (Child-Pugh A) but has not been studied in moderate or severe hepatic impairment [2]. Diphenhydramine clearance also decreases in liver disease. No additive hepatotoxicity mechanism exists between the two drugs, but reduced clearance of diphenhydramine could intensify its sedative and anticholinergic effects.

Renal Impairment

Inclisiran AUC increases approximately 2.3-fold in severe renal impairment (eGFR 15 to 29 mL/min/1.73m²), though no dose adjustment is recommended by the FDA [2]. Diphenhydramine's renally-excreted metabolites may also accumulate. Again, these are independent pharmacokinetic phenomena, not a synergistic interaction.

Monitoring Recommendations

Standard Inclisiran Monitoring

Lipid panels should be checked at baseline, 90 days after the initial dose (just before the second dose), and periodically thereafter. Liver function tests are not required per the label but may be ordered at clinician discretion. Injection-site assessments should occur at each administration visit [2].

When Diphenhydramine Is Used Concurrently

No additional laboratory monitoring is needed for the combination. Clinical monitoring should focus on diphenhydramine's standalone adverse-effect profile:

• Sedation level, particularly in patients driving or operating machinery
• Anticholinergic symptoms (dry mouth, blurred vision, constipation, urinary hesitancy)
• Fall risk in patients over 65
• Duration of use (diphenhydramine is approved for short-term use; chronic use increases anticholinergic burden)

Practical Guidance for Patients

Patients on Leqvio who need an antihistamine for seasonal allergies, acute urticaria, or sleep can use diphenhydramine without concern for a drug-drug interaction with inclisiran. The decision to use diphenhydramine versus a second-generation antihistamine should be based on the patient's age, comorbidities, and tolerance of anticholinergic and sedative effects.

Short-Term Versus Long-Term Use

Occasional diphenhydramine use (a single 25 to 50 mg dose for acute allergic symptoms or short-term insomnia) poses minimal risk in otherwise healthy adults under 65. Chronic nightly use for sleep, however, is discouraged by both the American Academy of Sleep Medicine and the Beers Criteria regardless of other medications [12][13].

OTC Combination Products

Diphenhydramine is an ingredient in many OTC combination products: cold formulas, sleep aids, and motion-sickness tablets. Patients should check labels to avoid inadvertent diphenhydramine duplication, but none of these formulations create a new interaction concern with inclisiran.

How Inclisiran Differs from Statins in Interaction Risk

Statins (atorvastatin, simvastatin, rosuvastatin) are CYP3A4- or CYP2C9-substrates with well-documented drug interaction profiles. Patients transitioning from statin monotherapy to statin-plus-inclisiran regimens sometimes assume inclisiran carries the same interaction baggage. It does not.

The PCSK9-targeting monoclonal antibodies (evolocumab, alirocumab) share this favorable interaction profile. Biologics and siRNA therapeutics bypass CYP metabolism, making their drug-interaction potential inherently lower than small-molecule drugs [14]. For patients on complex medication regimens, this is a clinically meaningful advantage.

Summary of the Evidence

The interaction between inclisiran and diphenhydramine is, pharmacologically, a non-interaction. Their metabolic pathways do not cross: inclisiran is degraded by nucleases, diphenhydramine is oxidized by CYP2D6. Their pharmacodynamic targets (PCSK9 mRNA vs. H1/muscarinic receptors) have no overlap. No dose adjustment, additional monitoring, or timing separation is required. The only actionable clinical consideration is ensuring that diphenhydramine use itself is appropriate for the patient's age, comorbidity profile, and duration of need. For adults under 65 using diphenhydramine occasionally, co-administration with Leqvio requires no special precautions. For adults 65 and older, a second-generation antihistamine is preferred per Beers Criteria [12], but that recommendation applies with or without inclisiran on board.